About:Stamulumab

An Entity of Type:monoclonal antibody,from Named Graph:http://dbpedia.org,within Data Space:dbpedia.org

Stamulumab (MYO-029) is an experimental myostatin inhibiting drug developed by Wyeth Pharmaceuticals for the treatment of muscular dystrophy (MD). Stamulumab was formulated and tested by Wyeth in Collegeville, Pennsylvania. Myostatin is a protein that inhibits the growth of muscle tissue, stamulumab is a recombinant human antibody designed to bind to and inhibit the activity of myostatin.

Property	Value
dbo:abstract	Stamulumab (MYO-029) is an experimental myostatin inhibiting drug developed by Wyeth Pharmaceuticals for the treatment of muscular dystrophy (MD). Stamulumab was formulated and tested by Wyeth in Collegeville, Pennsylvania. Myostatin is a protein that inhibits the growth of muscle tissue, stamulumab is a recombinant human antibody designed to bind to and inhibit the activity of myostatin. Stamulumab is a G1 immunoglobulin antibody which binds to myostatin and prevents it from binding to its target site, thus inhibiting the growth-limiting action of myostatin on muscle tissue. Research completed in 2002 found that Stamulumab might one day prove to be an effective treatment for Duchenne muscular dystrophy. (en)
dbo:casNumber	705287-60-1
dbo:fdaUniiCode	V43X8G4797
dbo:kegg	D05917
dbo:wikiPageID	9701299 (xsd:integer)
dbo:wikiPageLength	5208 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1074038997 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Annals_of_Neurology dbc:Wyeth_brands dbc:Abandoned_drugs dbr:Collegeville,_Pennsylvania dbc:Myostatin_inhibitors dbr:Antibody dbr:Limb-girdle_muscular_dystrophy dbr:Clinical_trial dbr:G1_phase dbr:Duchenne_muscular_dystrophy dbr:Facioscapulohumeral_muscular_dystrophy dbr:Becker's_muscular_dystrophy dbr:Protein dbr:Recombinant_DNA dbr:ACVR2B dbc:Monoclonal_antibodies dbr:Cohort_study dbr:Immunoglobulin dbr:Wyeth dbr:Muscular_dystrophy dbr:Myostatin
dbp:atcPrefix	none (en)
dbp:c	6330 (xsd:integer)
dbp:casNumber	705287 (xsd:integer)
dbp:chemspiderid	none (en)
dbp:h	9748 (xsd:integer)
dbp:kegg	D05917 (en)
dbp:mabType	mab (en)
dbp:n	1672 (xsd:integer)
dbp:o	1668 (xsd:integer)
dbp:routesOfAdministration	injection only (en)
dbp:s	48 (xsd:integer)
dbp:source	u (en)
dbp:target	dbr:Myostatin
dbp:type	mab (en)
dbp:unii	V43X8G4797 (en)
dbp:verifiedfields	changed (en)
dbp:verifiedrevid	470470459 (xsd:integer)
dbp:watchedfields	changed (en)
dbp:wikiPageUsesTemplate	dbt:Monoclonals_for_bone,_musculoskeletal,_circulatory,_and_neurologic_systems dbt:Drugbox dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Fdacite dbt:Keggcite dbt:Muscular_Dystrophy dbt:TGFβ_receptor_superfamily_modulators
dcterms:subject	dbc:Wyeth_brands dbc:Abandoned_drugs dbc:Myostatin_inhibitors dbc:Monoclonal_antibodies
gold:hypernym	dbr:Myostatin
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody dbo:Drug
rdfs:comment	Stamulumab (MYO-029) is an experimental myostatin inhibiting drug developed by Wyeth Pharmaceuticals for the treatment of muscular dystrophy (MD). Stamulumab was formulated and tested by Wyeth in Collegeville, Pennsylvania. Myostatin is a protein that inhibits the growth of muscle tissue, stamulumab is a recombinant human antibody designed to bind to and inhibit the activity of myostatin. (en)
rdfs:label	Stamulumab (en)
owl:sameAs	freebase:Stamulumab yago-res:Stamulumab wikidata:Stamulumab https://global.dbpedia.org/id/4vErk
prov:wasDerivedFrom	wikipedia-en:Stamulumab?oldid=1074038997&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:Stamulumab
isdbo:wikiPageRedirects of	dbr:MY0-029 dbr:MYO-029
isdbo:wikiPageWikiLink of	dbr:Activin_type_2_receptors dbr:Facioscapulohumeral_muscular_dystrophy dbr:List_of_therapeutic_monoclonal_antibodies dbr:Myostatin dbr:List_of_drugs:_Sp–Sub dbr:MY0-029 dbr:MYO-029
isfoaf:primaryTopic of	wikipedia-en:Stamulumab

Movatterモバイル変換

About:Stamulumab